{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:05:09Z","timestamp":1784048709721,"version":"3.55.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rhino-orbital-cerebral mucormycosis (ROCM) is an aggressive infection caused by Mucorales fungi, with rapid progression, high mortality, and disability. The insidious onset and atypical early symptoms predispose the condition to misdiagnosis or delayed diagnosis. There are no evidence-based guidelines for the diagnosis and treatment of mucormycosis in children. This case report describes the entire diagnostic and treatment process for a 14-year-old female patient with type 1 diabetes mellitus (T1DM) who developed ROCM following diabetic ketoacidosis (DKA). It highlights the key role of clinical pharmacists in multidisciplinary collaboration, pharmacological evaluation, antifungal regimen optimization, and medication monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>\n                      A 14-year-old female patient was admitted to the hospital due to persistent chest pain for 5\u202fdays and was diagnosed with T1DM complicated with DKA. During the treatment of DKA, the patient suddenly developed high fever, nasal congestion, progressive eyelid and periorbital swelling, headache, and cranial nerve dysfunction. Plasma mNGS and nasal mucosa biopsy both detected Rhizopus delemar, confirming ROCM. The initial treatment was liposomal amphotericin B (5\u202fmg\/kg\/d) combined with nasal endoscopic debridement, the infection was initially controlled. However, on the 16th day, anemia aggravated (Hb 84\u202fg\/L), and severe hypokalemia (K\n                      <jats:sup>+<\/jats:sup>\n                      2.41\u202fmmol\/L) occurred. After a multidisciplinary assessment led by a clinical pharmacist and completion of a 4-week course of liposomal amphotericin B, the treatment plan was adjusted to include oral isavuconazole and intranasal amphotericin B deoxycholate. Follow-up for 4\u202fmonths, facial and periorbital swelling completely resolved, olfaction recovered, facial sensation partially recovered, and no significant adverse drug reactions occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that in adolescent patients with T1DM who develop ROCM following DKA, non-specific prodromal symptoms such as headache, facial swelling, and nasal congestion should be closely monitored. Early implementation of a multi-modal diagnostic approach combining mNGS and tissue biopsy is necessary. Based on organ function, drug toxicity, and pharmacokinetic characteristics, individualized antifungal regimens that balance efficacy and target organ protection should be formulated. Clinical pharmacists play a crucial role in the management of severe fungal infections by participating in diagnostic collaboration, regimen optimization, and continuous safety monitoring, thereby enhancing the scientificity, safety, and precision of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1847375","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:11:49Z","timestamp":1784045509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinxin","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Wenzhou Central Hospital","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishu","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wenzhou Central Hospital","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/ofid\/ofad527","article-title":"Diverse clinical manifestations and challenges of mucormycosis: insights from serial cases","volume":"10","author":"Nielsen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJMra2412565","article-title":"Mucormycosis","volume":"394","author":"Kontoyiannis","year":"2026","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/1469-0691.12360","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/diagnostics14030314","article-title":"From spores to solutions: a comprehensive narrative review on mucormycosis","volume":"14","author":"Gull\u00ec","year":"2024","journal-title":"Diagnostics"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"738983","DOI":"10.3389\/fmicb.2021.738983","article-title":"Newer horizon of mesenchymal stem cell\u2013based therapy in the management of SARS-CoV-2\u2013associated mucormycosis: a safe hope for future medicine","volume":"12","author":"Raghav","year":"2021","journal-title":"Front Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12879-020-05460-2","article-title":"Orbital mucormycosis in immunocompetent children: review of risk factors, diagnosis, and treatment approach","volume":"20","author":"Amanati","year":"2020","journal-title":"BMC Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1715663","DOI":"10.3389\/fmed.2026.1715663","article-title":"Novel diagnostic approaches and therapeutic management of mucormycosis: insights from a retrospective monocentric cohort study","volume":"13","author":"Lemhamdi","year":"2026","journal-title":"Front Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2147\/idr.s462725","article-title":"Clinical characteristics and prognoses of mucormycosis in four children","volume":"17","author":"Li","year":"2024","journal-title":"Infect Drug Resist"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European conference on infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the society of infectious diseases pharmacists: endorsed by the mycoses study group education and research consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/mmy\/myab035","article-title":"Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring","volume":"59","author":"Davis","year":"2021","journal-title":"Med Mycol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"125131","DOI":"10.1016\/j.jaci.2004.09.037","article-title":"Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebocontrolled, doubleblind pilot trial [J]","volume":"115","author":"Ponikau","year":"2005","journal-title":"J Allergy Clin Immunol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12882-022-02770-2","article-title":"Tolerability and epidemiology of nephrotoxicity associated with conventional amphotericin B therapy: a retrospective study in tertiary care centers in Palestine","volume":"23","author":"Abdel-Hafez","year":"2022","journal-title":"BMC Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2131\/fts.8.147","article-title":"Relationship between renal dysfunction and change in serum electrolyte levels in patients administered with liposomal amphotericin B","volume":"8","author":"Yamashiro","year":"2021","journal-title":"Fundam Toxicol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/mmy\/myx104","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1847375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:11:51Z","timestamp":1784045511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1847375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1847375"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1847375","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1847375"}}